Skip to main content

Advertisement

Log in

The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes

  • Original Investigation
  • Published:
Medical Microbiology and Immunology Aims and scope Submit manuscript

Abstract

The SnoB study analysed the variability of the integrase (IN) gene of non-B viruses from treatment-naïve patients to determine whether non-B subtypes carry natural resistance mutations to raltegravir (RAL). Plasma viral RNA from 427 patients was gained, and IN sequences were subtyped and screened for subtype-specific highly-variable residues. Seven viruses of different subtypes were phenotypically tested for RAL susceptibility; 359/427 samples could be sequenced. One hundred and seventy samples (47%) were classified as non-B subtypes. No primary RAL resistance–associated mutations (RRAMs) were detected. Certain secondary mutations were found, mostly related to specific non-B subtypes. L74 M was significantly more prevalent in subtype 02_AG, T97A in A and 06_cpx, V151I in 06_cpx, and G163R in 12_BF. Various additional mutations were also detected and could be associated with the subtype too. While K156 N and S230 N were correlated with B subtype, V72I, L74I, T112I, T125A, V201I and T206S were more frequent in certain non-B subtypes. The resistance factors (RF) of 7 viral strains of different subtypes ranged from 1.0 to 1.9. No primary or secondary but subtype-associated additional RRAMs were present. No correlation between RF and additional RRAMs was found. The prevalence of RRAMs was higher in non-B samples. However, the RFs for the analysed non-B subtypes showed lower values to those reported relevant to clinical failure. As the role of baseline secondary and additional mutations on RAL therapy failure is actually not known, baseline IN screening is necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H (2006) Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 43(5):509–515

    Article  PubMed  CAS  Google Scholar 

  2. Grinsztejn B, Nguyen BY, Katlama C, Gatell J, Lazzarin A, Vittecoq D, Gonzalez C, Chen J, Isaacs R, Team Tps (2006) Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 13th conference on retroviruses and opportunistic infections (CROI), Denver, USA, 5–8 February 2006. p Abstract 159LB

  3. Cooper D, Gatell J, Rockstroh J, Katlama C, Yeni P, Lazzarin A, Chen J, Isaacs R, Teppler H, Nguyen B, Group B-S (2007) Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 14th conference on retroviruses and opportunistic infections (CROI), Los Angeles, CA, USA, 25–28 February 2007. p Abstract 105aLB

  4. Steigbigel R, Kumar P, Eron J, Schechter M, Markowitz M, Loufty M, Zhao J, Isaacs R, Nguyen BY, Teppler H, Group tB-S (2007) Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 14th conference on retroviruses and opportunistic infections (CROI), Los Angeles, CA, USA, 25–28 February 2007. p Abstract 105bLB

  5. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, Kearney BP, Cheng AK (2010) Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 201(6):814–822. doi:10.1086/650698

    Article  PubMed  CAS  Google Scholar 

  6. Arribas J, Lazzarin A, Raffi F, Rakhmanova A, Richmond G, Rockstroh J, van Lunzen J, Young B, Almond S, Brothers C, Min S, Nichols G (2010) Once-daily S/GSK1349572 as part of combination therapy in antiretroviral naïve adults: rapid and potent antiviral responses in the interim 16-week analysis from SPRING-1 (ING112276). In: 18th international conference on AIDS, Vienna, Austria, 2010. p Abstract THLBB205

  7. Eron J, Durant J, Poizot-Martin I, Reynes J, Soriano V, Kumar P, Richmond G, Vittecoq D, Fujiwara T, Ait-Khaled M, Min S, Thomas D, Cuffe R, Yeo J (2010) Activity of a next generation integrase inhibitor (INI), S/GSK1349572, in subjects with HIV exhibiting raltegravir resistance: initial results of VIKING study (ING112961). In: 18th international conference on AIDS, Vienna, Austria, 2010. p Abstract MOAB0105

  8. DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, Elion R, Farthing C, Zhong L, Cheng AK, McColl D, Kearney BP (2006) Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 43(1):1–5

    Article  PubMed  CAS  Google Scholar 

  9. Grinsztejn B, Nguyen B, Katlama CB, Gatell J, Lazzarin A, Vittecoq D, Gonzalez C, Chen J, Isaacs R, Team TP (2007) 48 week efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 47th ICAAC, Chicago, 2007. Abstract H-713

  10. Hazuda DJ, Miller MD, Nguyen BY, Zhao J (2007) Resistance to HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection. Antiviral Ther 12:10

    Google Scholar 

  11. Lennox J, DeJesus E, Lazzarin A, Pollard R, Madruga JVR, Zhao J, Xu X, Williams-Diaz A, Rodgers A, DiNubile M, Nguyen BY, Leavitt R, Sklar P, Investigators tS (2008) Safety and efficacy of Raltegravir-based versus Efavirenz-based combination therapy in treatment naive HIV-1 infected patients. STARTMRK protocol 021. In: ICAAC-IDSA Washington DC, USA, 2008. Abstract H-896a

  12. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM (2008) The challenge of HIV-1 subtype diversity. N Engl J Med 358(15):1590–1602

    Article  PubMed  CAS  Google Scholar 

  13. Deforche K, Silander T, Camacho R, Grossman Z, Soares MA, Van Laethem K, Kantor R, Moreau Y, Vandamme AM (2006) Analysis of HIV-1 pol sequences using Bayesian networks: implications for drug resistance. Bioinformatics 22(24):2975–2979

    Article  PubMed  CAS  Google Scholar 

  14. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, Shafer RW (2005) Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2(4):e112

    Article  PubMed  Google Scholar 

  15. Sichtig N, Sierra S, Kaiser R, Däumer MP, Reuter S, Schülter E, Altmann A, Fäktenheuer G, Dittmer U, Pfister H, Esser S (2009) Raltegravir resistance mutation profiles: baseline situation and modification during treatment. J Antimicrob Chemother 64(1):25–32

    Article  PubMed  CAS  Google Scholar 

  16. Stürmer M, Doerr HM, Gürtler L (2009) Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus. Med Microbiol Immunol 198(3):147–155. doi:10.1007/s00430-009-0117-6

    Google Scholar 

  17. Fransen S, Grupta S, Danovich R, Hazuda DJ, Miller M, Witmer M, Petropoulos CJ, Parkin NT, Huang W (2008) Loss of raltegravir susceptibility in treated patients is conferred by multiple non-overlapping genetic pathways. Antiviral Ther 13(Suppl 3):A9

    Google Scholar 

  18. Fransen S, Karmochkine M, Huang W, Weiss L, Petropoulos CJ, Charpentier C (2009) Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother 53(10):4522–4524. doi:10.1128/AAC.00651-09

    Article  PubMed  CAS  Google Scholar 

  19. Miller MD, Danovich RM, Ke Y, Witmer M, Zhao J, Harvey CM, Nguyen BY, Hazuda DJ (2008) Longitudinal analysis of resistance to the HIV-1 integrase inhibitor reltegravir: results from P005 a phase II study in treatment-experienced patients. Antiviral Ther 13(Suppl 3):A8

    Google Scholar 

  20. Anies G, da Silva D, Recordon-Pinson P, Reigadas S, Wittkop L, Neau D, Morlat P, Fleury H, Masquelier B (2009) Analysis of raltegravir-resistant patterns including mutations at positions 143 and 155 in the HIV-1 integrase. In: 16th conference on retroviruses and opportunistic infections (CROI), San Francisco, CA, USA, February 16–19, 2009. Abstract 619

  21. Jones G, Ledford R, Yu F, Miller M, Tsiang M, McColl D (2007) Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). In: 14th conference on retroviruses and opportunistic infections (CROI), Los Angeles, CA, USA, 25–28 February 2007. Foundation for retrovirology and human health, Alexandria, VA, USA, p Abstract 627

  22. Hackett Jr J, Harris B, Holzmayer V, Yamaguchi J, Luk KC, Brennan C, Schochetman G, Devare S, Swanson P (2008) Naturally occurring polymorphisms in HIV-1 group M, N, and O integrase: implications for integrase inhibitors. In: 15th conference on retroviruses and opportunistic infections (CROI), Boston, MA, USA, 3–6 February 2008. Foundation for retrovirology and human health, Alexandria, VA, USA, p Abstract 872

  23. Garrido C, Geretti AM, de Mendoza C, Booth C, Strang A, Soriano V Polymorphisms at the integrase gene in distinct HIV populations may influence the susceptibility to integrase inhibitors. In: 6th European HIV Drug Resistance Workshop, Budapest, Hungary, 26-28 March 2008. Virology Education, BJ Utrecht, Netherlands, p Abstract 12

  24. Yerly S, Hirschel B, Gaille C, Kaiser L, Perrin L (2007) Polymorphism of HIV-1 subtypes B and non-B integrase gene. In: 14th conference on retroviruses and opportunistic infections (CROI), Los Angeles, CA, USA, 25–28 February 2007. Foundation for retrovirology and human health, Alexandria, VA, USA, p Abstract 626

  25. Lataillade M, Chiarella J, Kozal MJ (2007) Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 12(4):563–570

    PubMed  CAS  Google Scholar 

  26. Myers RE, Pillay D (2007) HIV-1 integrase sequence variation and covariation. Antiviral Ther 12:5

    Google Scholar 

  27. Van Baelen K, Rondelez E, Van Eygen V, Smits V, Van den Zegel P, Stuyver LJ (2008) Validation of a genotypic and phenotypic recombinant viruses assay to determine resistance against HIV-1 inhibitors. Antiviral Ther 13(Suppl 3):A127

    Google Scholar 

  28. Goodman D, Hluhanich R, Waters J, Margot NA, Fransen S, Gupta S, Huang W, Parkin N, Borroto-Esoda K, Svarovskaia ES, Miller MD, McColl DJ (2008) Integrase inhibitor resistance involves complex interactions among primary and secondary resistance mutations: a novel mutation L68 V/I associates with E92Q and increases resistance. In: XVII international HIV drug resistance workshop sitges, Spain, 2008. p Abstract 7

  29. Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ (2008) Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS 22(14):1877–1880. doi:10.1097/QAD.0b013e32830f9703

    Article  PubMed  Google Scholar 

  30. Hu Z, Kuritzkes DR (2010) Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 55(2):148–155. doi:10.1097/QAI.0b013e3181e9a87a

    Article  PubMed  CAS  Google Scholar 

  31. Ceccherini-Silberstein F, Armenia D, D’Arrigo R, Micheli V, Fabeni L, Meraviglia P, Capetti A, Zaccarelli M, Trotta MP, Narciso P, Antinori A, Perno CF (2008) Virological response and resistance in multi-experienced patients treated with raltegravir. Antiviral ther 13(Suppl 3):A15

    Google Scholar 

  32. Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, Baril JG, Wainberg MA, Roger M (2011) Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol

  33. da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, Fleury H, Masquelier B (2010) HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 65(6):1262–1269

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Dörte Hammerschmidt for invaluable help in sample processing and MSD for supporting this study.

Ethical standards

Ethics approval was given from the responsible ethics committees.

Conflicts of interest

The authors have not any commercial or other association that may pose a conflict of interest with this manuscript.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Saleta Sierra.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sierra, S., Lübke, N., Walter, H. et al. The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes. Med Microbiol Immunol 200, 225–232 (2011). https://doi.org/10.1007/s00430-011-0194-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00430-011-0194-1

Keywords

Navigation